葛兰素史克(GSK)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

GSK 葛兰素史克

交易中 10-14 13:01:06 EDT

47.83

+1.56

+3.37%

最高47.92	最低46.55	成交量418.67万
今开46.59	昨收46.27	日振幅2.95%
总市值967.46亿	流通市值927.90亿	总股本20.23亿
成交额1.99亿	换手率0.22%	流通股本19.40亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"GSK","market":"US","secType":"STK","nameCN":"葛兰素史克","latestPrice":47.83,"timestamp":1791997265173,"preClose":46.27,"halted":0,"volume":4186683,"delay":0,"changeRate":0.03371515020531651,"floatShares":1939999999,"shares":2022697682,"eps":3.127128,"marketStatus":"交易中","change":1.56,"latestTime":"10-14 13:01:06 EDT","open":46.59,"high":47.915,"low":46.55,"amount":198752547.358431,"amplitude":0.029501,"askPrice":47.83,"askSize":525,"bidPrice":47.82,"bidSize":126,"shortable":3,"etf":0,"ttmEps":3.127128,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1792008000000},"marketStatusCode":2,"adr":1,"adrRate":2,"listingDate":977893200000,"exchange":"NYSE","adjPreClose":46.27,"dividendRate":0.038087,"preHourTrading":{"tag":"盘前","latestPrice":46.67,"preClose":46.27,"latestTime":"09:29 EDT","volume":26218,"amount":1221146.688354,"timestamp":1791984599999,"change":0.4,"changeRate":0.008645,"amplitude":0.008429},"postHourTrading":{"tag":"盘后","latestPrice":46.2975,"preClose":46.27,"latestTime":"19:56 EDT","volume":54835,"amount":2537849.5775,"timestamp":1791935781290,"change":0.0275,"changeRate":0.000594,"amplitude":0.000594},"volumeRatio":1.007369,"impliedVol":0.372,"impliedVolPercentile":0.9801},"requestUrl":"/m/hq/s/GSK","defaultTab":"news","newsList":[{"id":"1101882516","title":"异动解读｜葛兰素史克盘中上涨3.03%，比利时疫苗业务重组计划受关注","url":"https://stock-news.laohu8.com/highlight/detail?id=1101882516","media":"行情直击","labels":["corporation"],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101882516?lang=zh_cn&edition=full","pubTime":"2026-10-14 23:24","pubTimestamp":1791991499,"startTime":"0","endTime":"0","summary":"10月14日，葛兰素史克盘中上涨3.03%，报47.67美元/股，成交额8913.55万美元。消息面上，公司被报道拟重组比利时疫苗业务，并在当地最多裁减1217个岗位。此次调整涉及瓦夫尔、里克斯萨特和根布卢三个基地，主要影响研发、行政及全球支持部门，一线生产人员 reportedly 不受影响，后续还将与工会展开协商。此外，市场近期也在关注公司新一轮成本节约计划。机构最新预期其第三季度业绩整体大致符合预期，年内焦点正转向成本优化与后续关键临床启动。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"葛兰素史克盘中上涨，疫苗重组与成本优化引关注","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675310120","title":"据报葛兰素史克（GSK）正重组疫苗业务 拟在比利时裁员至多1217人","url":"https://stock-news.laohu8.com/highlight/detail?id=2675310120","media":"金吾财讯","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675310120?lang=zh_cn&edition=full","pubTime":"2026-10-14 17:43","pubTimestamp":1791971037,"startTime":"0","endTime":"0","summary":"金吾财讯 | 据多家外媒周三报道，英国制药巨头葛兰素史克（GSK）已向企业委员会正式宣布重组计划，拟在其位于比利时的三个疫苗业务基地（瓦夫尔、里克斯萨特和根布卢）裁减至多1217个职位。报道称，本次裁员主要集中于旗下负责疫苗研发与生产的葛兰素史克生物制品公司（GSK Biologicals），受影响群体涵盖研发、行政及全球支持部门的员工与管理人员，而一线生产人员则不受影响。根据比利时劳工法律（即“雷诺程序”），GSK在实施集体裁员前必须与工会展开四阶段的结构化协商。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250107/ODI2NGE1NjlmODgxZDI1NzFmMmQ4ODQzNDA1OTI5NjU2Mg==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ODI2NGE1NjlmODgxZDI1NzFmMmQ4ODQzNDA1OTI5NjU2Mg==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"307174","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","159646","BK4532","GSK.UK","GSK","GSKH","BK4585","BK4588","LU1829250122.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165449525","title":"异动解读｜葛兰素史克盘中下跌3.04%，报49.515美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1165449525","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165449525?lang=zh_cn&edition=full","pubTime":"2026-09-18 23:09","pubTimestamp":1789744170,"startTime":"0","endTime":"0","summary":"9月18日，葛兰素史克盘中下跌3.04%，报49.515美元/股，成交额4074.3万美元。葛兰素史克所在的制药行业中，个股中，礼来跌0.81%，强生跌0.77%，IM Cannabis Corp涨253.45%，默沙东跌0.71%，辉瑞跌0.92%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668694451","title":"全球药企“抢滩”中国管线：从成本嫁接走向早期合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2668694451","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668694451?lang=zh_cn&edition=full","pubTime":"2026-09-18 17:14","pubTimestamp":1789722892,"startTime":"0","endTime":"0","summary":"从“产品出海”到“生态融合”，中国生物医药的全球化合作出现新的变化。国家药监局数据显示，2026年1—6月，中国创新药对外授权交易共81笔，总额约1100亿美元，已达2025年全年总额的八成，创历史新高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609183878667977.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609183878667977.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["GSK.UK","LU1829250122.USD","GSK","BK4007","BK4532","GSKH","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667637649","title":"葛兰素史克（GSK）拟斥资7.5亿美元收购Chimagen旗下TCE项目全球独家权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2667637649","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667637649?lang=zh_cn&edition=full","pubTime":"2026-09-15 18:32","pubTimestamp":1789468371,"startTime":"0","endTime":"0","summary":"金吾财讯 | 葛兰素史克（GSK）已与Chimagen Biosciences达成协议，将以高达7.5亿美元的交易总额，收购后者一款用于治疗多发性骨髓瘤的三特异性T细胞衔接器（TCE）项目的全球独家权益。根据协议，GSK将向Chimagen支付一笔首付款，并根据后续研发与商业化进展支付相应的里程碑付款。该候选药物能够同时靶向T细胞及两种肿瘤相关抗原，目前预计将于2027年正式进入I期临床试验阶段。此前，双方已就另一款处于I期临床、针对CD19/CD20的双重TCE药物CMG1A46达成合作，本次交易标志着GSK在多发性骨髓瘤及血液瘤产品线上的进一步深化布局。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250107/ODI2NGE1NjlmODgxZDI1NzFmMmQ4ODQzNDA1OTI5NjU2Mg==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ODI2NGE1NjlmODgxZDI1NzFmMmQ4ODQzNDA1OTI5NjU2Mg==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"306052","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4588","LU1829250122.USD","BK4585","BK4532","GSK","GSKH","GSK.UK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111956752","title":"异动解读｜葛兰素史克盘中上涨4.07%，肺癌药Jideytro一线试验达94%缓解率","url":"https://stock-news.laohu8.com/highlight/detail?id=1111956752","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111956752?lang=zh_cn&edition=full","pubTime":"2026-09-14 21:38","pubTimestamp":1789393100,"startTime":"0","endTime":"0","summary":"9月14日，葛兰素史克盘中上涨4.07%，报50.0美元/股，成交额2419.23万美元。消息面上，公司公布旗下肺癌药物zidesamtinib一线治疗临床试验数据，在未经靶向治疗的晚期ROS1阳性肺癌患者中实现94%的客观缓解率；脑转移患者应答率达100%，其中70%实现完全肿瘤清除。公司计划年内向FDA提交一线适应症扩展申请。此外，GSK授权方翰森制药报告其ADC药物Ris-Rez治疗复发性小细胞肺癌的III期试验达到主要终点，进一步提振市场对GSK肿瘤管线的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"葛兰素史克盘中上涨，肺癌新药缓解率达94%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120774041","title":"异动解读｜葛兰素史克盘前上涨3.32%，肺癌药Jideytro一线试验达94%缓解率远超同类","url":"https://stock-news.laohu8.com/highlight/detail?id=1120774041","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120774041?lang=zh_cn&edition=full","pubTime":"2026-09-14 18:02","pubTimestamp":1789380156,"startTime":"0","endTime":"0","summary":"9月14日，葛兰素史克盘前上涨3.32%，报49.73美元/股，成交额84.86万美元。公司计划年内向FDA提交一线适应症扩展申请。Jideytro是GSK首个商业化肺癌药物，此前已获FDA批准用于经治ROS1阳性肺癌，一线数据的强劲表现为其\"重磅炸弹级\"销售潜力提供了有力支撑。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"葛兰素史克盘前上涨，肺癌新药缓解率达94%","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665937331","title":"乙肝新药中国数据出炉，但实现患者的“治愈梦”仍有门槛","url":"https://stock-news.laohu8.com/highlight/detail?id=2665937331","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665937331?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:51","pubTimestamp":1788871868,"startTime":"0","endTime":"0","summary":"中国慢性乙型肝炎（以下简称慢乙肝）患者的“治愈”故事，正在萌芽。日前，在新加坡召开的亚洲肝病学峰会暨乙肝病毒治愈科学会议上，反义寡核苷酸（ASO）药物Bepirovirsen全球Ⅲ期研究（BWell研究）的中国人群数据完成了全球首秀：中国慢乙肝患者功能性治愈率最高可达61%，疗效与安全性趋势与全球数据一致。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609083868286383.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609083868286383.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","ASO","BK4561","BK4585","LU1829250122.USD","BK4532","BK4007","BK4200","GSK.UK","GSK","GSKH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665535012","title":"功能性治愈率最高61%！乙肝新药中国数据出炉 但7500万患者的“治愈梦”仍有门槛","url":"https://stock-news.laohu8.com/highlight/detail?id=2665535012","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665535012?lang=zh_cn&edition=full","pubTime":"2026-09-05 12:14","pubTimestamp":1788581677,"startTime":"0","endTime":"0","summary":"【功能性治愈率最高61%！乙肝新药中国数据出炉 但7500万患者的“治愈梦”仍有门槛】8月31日—9月5日，在新加坡召开的亚洲肝病学峰会（AHS）暨HBV（乙型肝炎病毒）治愈科学会议上，反义寡核苷酸（ASO）药物Bepirovirsen全球Ⅲ期研究（B-Well研究）的中国人群数据完成了全球首秀：中国慢乙肝患者功能性治愈率最高可达61%，疗效与安全性趋势与全球数据一致。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609053865995314.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609053865995314.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","GSK","ALT","LU1829250122.USD","ASO","GDXJ","LU1223083913.SGD","SGDM","BK4599","BK4200","GSK.UK","LU1223082196.USD","BK4532","BK4007","BK4561","GSKH","LU1223082519.USD","BK4017","CHB","XME","LU1878469433.USD","SIL","BK4139","BK4585","CDE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664960827","title":"总额可达12.95亿美元！和黄全球首创偶联药物出海","url":"https://stock-news.laohu8.com/highlight/detail?id=2664960827","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664960827?lang=zh_cn&edition=full","pubTime":"2026-09-03 16:03","pubTimestamp":1788422625,"startTime":"0","endTime":"0","summary":"9月3日，和黄医药（00013.HK）宣布旗下子公司和记黄埔与葛兰素史克（GSK）附属公司达成独家开发及许可协议，授予后者除中国大陆、香港、澳门和台湾以外的全球范围内开发和商业化HMPL-A830的权利。临床开发将首先聚焦于结直肠癌、胰腺癌和肺癌适应症。协议包括1.1亿美元的首付款以及潜在的开发、注册和商业化里程碑付款，总额可达12.95亿美元，外加基于净销售额的特许权使用费。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609033864044420.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609033864044420.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1587","BK4588","BK4007","BK1588","00013","GSKH","BK4532","GSK.UK","GSK","LU1829250122.USD","BK4585","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124565155","title":"和黄医药午后飙升逾16%，与葛兰素史克达成最高12.95亿美元肿瘤药授权合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1124565155","media":"老虎资讯综合","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124565155?lang=zh_cn&edition=full","pubTime":"2026-09-03 15:56","pubTimestamp":1788422188,"startTime":"0","endTime":"0","summary":"$和黄医药(00013)$周四午后股价大幅走高，一度升逾16%，势创2022年11月以来最大单日升幅。消息面上，和黄医药周四宣布，旗下公司与$葛兰素史克(GSK)$附属公司签署独家开发及许可协议，双方将合作开发及商业化在研肿瘤药物HMPL-A830。根据协议，和黄医药将获得1.1亿美元首付款，并有权获得最高12.95亿美元的开发、监管及商业化里程碑付款，以及产品上市后的净销售额特许权使用费。受大额授权合作消息刺激，和黄医药午后获资金明显追捧，股价升幅迅速扩大。","market":"us","thumbnail":"https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSKH","GSK","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662081157","title":"葛兰素史克(GSK)拟发行至少20亿欧元债券，以偿还并购融资贷款。","url":"https://stock-news.laohu8.com/highlight/detail?id=2662081157","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662081157?lang=zh_cn&edition=full","pubTime":"2026-08-27 18:00","pubTimestamp":1787824828,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LQPE","FYLG","BK4007","LBO","ARB","LU1829250122.USD","MRGR","NBIE","BK4585","FXE","GSK","BK4532","TFNS","BNDW","RSPF","PEX","GSKH","MNA","BUYO","GSK.UK","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181045381","title":"异动解读｜葛兰素史克盘中上涨3.01%，制药板块集体走强叠加多重利好催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1181045381","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181045381?lang=zh_cn&edition=full","pubTime":"2026-08-20 03:09","pubTimestamp":1787166556,"startTime":"0","endTime":"0","summary":"8月20日，葛兰素史克盘中上涨3.01%，报52.685美元/股，成交额1.42亿美元。消息面上，制药板块当日集体走强，同业默沙东大涨13.16%、礼来涨4.82%、辉瑞涨3.89%，板块资金流入明显。公司层面，近日利好密集释放：8月18日，中外制药与GSK签署抗登革热病毒抗体AID351独家许可协议，GSK获得该药物全球独家开发、生产和商业化权利；同日，核心产品NUCALA获加拿大药品管理局积极报销推荐，适应症拓展至成人慢性阻塞性肺疾病。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660493380","title":"GSK：NUCALA获加拿大药品管理局积极报销推荐，用于成人慢性阻塞性肺疾病治疗。","url":"https://stock-news.laohu8.com/highlight/detail?id=2660493380","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660493380?lang=zh_cn&edition=full","pubTime":"2026-08-18 22:23","pubTimestamp":1787062997,"startTime":"0","endTime":"0","summary":null,"market":"uk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["GSK","GSK.UK","LU1829250122.USD","BK4007","BK4588","GSKH","BK4532","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660456776","title":"中外制药与葛兰素史克签署抗登革热病毒抗体“AID351”独家许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2660456776","media":"第一财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660456776?lang=zh_cn&edition=full","pubTime":"2026-08-18 10:49","pubTimestamp":1787021377,"startTime":"0","endTime":"0","summary":"【中外制药与葛兰素史克签署抗登革热病毒抗体“AID351”独家许可协议】据中外制药官网消息，8月18日，中外制药宣布已与葛兰素史克签署独家许可协议，葛兰素史克将获得抗登革热病毒抗体药物“AID351”的全球独家开发、生产和商业化权利，并负责该药物的临床开发及生产。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608183844335660.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608183844335660.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1829250122.USD","BK1191","BK4007","BK4585","GSKH","BK1574","GSK.UK","GSK","BK4588","BK4532","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660456160","title":"中外制药与葛兰素史克达成协议，共同推进登革热抗体药物开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2660456160","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660456160?lang=zh_cn&edition=full","pubTime":"2026-08-18 10:38","pubTimestamp":1787020681,"startTime":"0","endTime":"0","summary":null,"market":"uk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1829250122.USD","BK4007","BK4585","GSKH","GSK.UK","GSK","BK4588","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659945158","title":"葛兰素史克：董事会批准根据公司净资产，按资产市场价值分配公司合并后股本。","url":"https://stock-news.laohu8.com/highlight/detail?id=2659945158","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659945158?lang=zh_cn&edition=full","pubTime":"2026-08-13 17:58","pubTimestamp":1786615104,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","BK4588","BK4007","GSK","GSKH","LU1829250122.USD","GSK.UK","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655336136","title":"GSK上半年核心营业利润增长 管线优化同步推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2655336136","media":"经济参考网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655336136?lang=zh_cn&edition=full","pubTime":"2026-07-31 21:00","pubTimestamp":1785502815,"startTime":"0","endTime":"0","summary":"7月28日，葛兰素史克（GSK）公布2026年第二季度及上半年业绩。财报显示，今年上半年，葛兰素史克实现总营收160.38亿英镑，同比增长5%（以固定汇率计价，下同）；受期内药物临床试验失败等因素影响，公司总营业利润为27.74亿英镑，同比减少31%。不过，公司核心营业利润（剔除非经常性项目后的“常态化”利润）为54.50亿英镑，同比增长8%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607313828578150.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607313828578150.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","BK4588","BK4007","GSK","GSKH","LU1829250122.USD","GSK.UK","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654888584","title":"美股异动 | 医药板块走强 葛兰素史克(GSK.US)绩后大涨超7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654888584","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654888584?lang=zh_cn&edition=full","pubTime":"2026-07-28 22:50","pubTimestamp":1785250222,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4007","BK4588","BK4532","BK4585","GSK","GSKH","GSK.UK","LU1829250122.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117275596","title":"美股异动｜医药股板块普涨，葛兰素史克涨近7%，安进涨超5%，艾伯维公司涨近4%，辉瑞、默沙东涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1117275596","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117275596?lang=zh_cn&edition=full","pubTime":"2026-07-28 22:29","pubTimestamp":1785248946,"startTime":"0","endTime":"0","summary":"7月28日，医药股板块普涨，葛兰素史克涨近7%，安进涨超5%，艾伯维公司涨近4%，辉瑞、默沙东涨超3%，强生涨近3%，礼来涨超2%。消息面上，葛兰素史克公布的二季度财报显示，调整后每股收益为50.5便士，显著高于市场预期的46.8便士，盈利表现超出预期。与此同时，葛兰素史克宣布计划到2029年全面实现每年19亿英镑的成本节约，这一目标进一步增强了投资者对公司未来盈利能力的信心。","market":"us","thumbnail":"https://static.tigerbbs.com/abf9f2b56caccf2c92db82642df48d35","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/abf9f2b56caccf2c92db82642df48d35"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK","LLY","AMGN","LLII","PFE","MRK","ELIS","ELIL","JNJ","LLYZ","GSKH","ABBV","LLYX"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.gsk.com","stockEarnings":[{"period":"1week","weight":-0.0071},{"period":"1month","weight":-0.0386},{"period":"3month","weight":-0.1007},{"period":"6month","weight":-0.1901},{"period":"1year","weight":0.0591},{"period":"ytd","weight":-0.0565}],"compareEarnings":[{"period":"1week","weight":-0.0014},{"period":"1month","weight":0.018},{"period":"3month","weight":0.0307},{"period":"6month","weight":0.1088},{"period":"1year","weight":0.1734},{"period":"ytd","weight":0.1409}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"GSK Plc于1999年12月6日在英国成立的公众服务有限公司，是一个世界领先的研究型制药和保健公司，由Glaxo Wellcome plc和SmithKline Beecham plc合并而成。公司致力于开发较现有治疗方案明显改善的新产品，为病人和政府、保险公司或其他第三方提供帮助。","yearOnYearQuotes":[{"month":1,"riseRate":0.586957,"avgChangeRate":0.013809},{"month":2,"riseRate":0.478261,"avgChangeRate":0.001243},{"month":3,"riseRate":0.608696,"avgChangeRate":0.019112},{"month":4,"riseRate":0.659574,"avgChangeRate":0.030828},{"month":5,"riseRate":0.404255,"avgChangeRate":-0.008644},{"month":6,"riseRate":0.595745,"avgChangeRate":0.010234},{"month":7,"riseRate":0.531915,"avgChangeRate":0.003565},{"month":8,"riseRate":0.574468,"avgChangeRate":0.00509},{"month":9,"riseRate":0.510638,"avgChangeRate":0.004965},{"month":10,"riseRate":0.510638,"avgChangeRate":0.011945},{"month":11,"riseRate":0.478261,"avgChangeRate":0.009917},{"month":12,"riseRate":0.608696,"avgChangeRate":0.014188}],"exchange":"NYSE","name":"葛兰素史克","nameEN":"GlaxoSmithKline PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"葛兰素史克(GSK)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供葛兰素史克(GSK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"葛兰素史克,GSK,葛兰素史克股票,葛兰素史克股票老虎,葛兰素史克股票老虎国际,葛兰素史克行情,葛兰素史克股票行情,葛兰素史克股价,葛兰素史克股市,葛兰素史克股票价格,葛兰素史克股票交易,葛兰素史克股票购买,葛兰素史克股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"葛兰素史克(GSK)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供葛兰素史克(GSK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}